DEC 11, 2019 2:20 PM PST

Drug To Treat Ulcerative Colitis

WRITTEN BY: Nouran Amin

Biomedical researchers at the University of California—Riverside, found that the therapeutic drug ‘tofacitinib’ used in treating autoimmunity symptoms of rheumatoid arthritis can also treat gut permeability defects in patients diagnosed with ulcerative colitis. "Our work increases our understanding of how this drug is useful for treating ulcerative colitis," said Declan McCole, a professor of biomedical sciences in the UCR School of Medicine, and the lead author of the study that appears in the journal Inflammatory Bowel Diseases. "We now better understand where in the gut the drug is working, and how."

Ulcerative colitis is a chronic inflammatory bowel disease affecting 1 million Americans. The condition targets the large intestine in the digestive system that results in the lining of the colon becoming inflamed and leaky. But, tofacitinib—often marketed as Xeljianz—can repair the cells lining the gut.

"We found tofacitinib fixes the leakiness in the intestinal barrier," McCole said. "Specifically, it fixes intestinal epithelial permeability defects caused by 'interferon-gamma,' an inflammatory cytokine involved in autoimmune diseases such as ulcerative colitis and rheumatoid arthritis."

Learn more about ulcerative colitis:

Intestinal permeability, or leakiness, is a characteristic of ulcerative colitis and results in inflammation. Researchers believe that tofacitinib targets the inflammation-induced permeability in the lining and prevents fluid loss.

"By targeting specific molecules, the drug inhibits a pathway that is activated by inflammation," said Anica Sayoc-Becerra, a graduate student in the Biomedical Sciences Graduate Program, a member of McCole's lab, and the first author of the research paper. "Our study shows tofacitinib is not just acting on immune cells, as was first thought, but can have a direct effect on the epithelial cells that are the key factor in maintaining gut barrier function."

Source: University of California

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
AUG 10, 2020
Cardiology
Can Statins be Used to Treat Strokes?
AUG 10, 2020
Can Statins be Used to Treat Strokes?
When a blood clot forms in an artery that supplies the brain with oxygen, obstructing it, a stroke can occur. Strokes ca ...
AUG 18, 2020
Drug Discovery & Development
Researchers Discover Mechanism to Prevent Antibiotic Resistance
AUG 18, 2020
Researchers Discover Mechanism to Prevent Antibiotic Resistance
Researchers from the Monash Biomedicine Discovery Institute have discovered a method used by bacteria to develop antibio ...
AUG 22, 2020
Drug Discovery & Development
Could a Drug for Bipolar Disorder Treat COVID-19?
AUG 22, 2020
Could a Drug for Bipolar Disorder Treat COVID-19?
Researchers have found that a drug currently used to treat bipolar disorder and hearing loss may also treat COVID-19 tha ...
AUG 25, 2020
Cannabis Sciences
FDA Approves Cannabis Drug to Treat Rare Genetic Disease
AUG 25, 2020
FDA Approves Cannabis Drug to Treat Rare Genetic Disease
The US Food and Drug Administration has approved Epidiolex, a cannabidiol (CBD) oral solution, to treat seizures linked ...
SEP 08, 2020
Drug Discovery & Development
Common Steroid Drug Reduces COVID-19 Deaths by 20%
SEP 08, 2020
Common Steroid Drug Reduces COVID-19 Deaths by 20%
Hydrocortisone, a common and widely-available anti-inflammatory steroid drug, has been found to reduce the mortality rat ...
SEP 27, 2020
Cannabis Sciences
THC Shows Promise in Treating Severe Cases of COVID-19
SEP 27, 2020
THC Shows Promise in Treating Severe Cases of COVID-19
Over the last few months, various headlines have emerged suggesting the potential for cannabinoids, and in particular, c ...
Loading Comments...